1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Sweden >
  5. Marvell Acquires Xelerated AB

M&A Deal Summary

Marvell Acquires Xelerated AB

On January 4, 2012, Marvell acquired semiconductors company Xelerated AB from Alta Partners and Amadeus Capital Partners

Acquisition Highlights
  • This is Marvell’s 8th transaction in the Semiconductors sector.
  • This is Marvell’s 1st transaction in Sweden.

M&A Deal Summary
Date 2012-01-04
Target Xelerated AB
Sector Semiconductors
Buyer(s) Marvell
Sellers(s) Alta Partners
Amadeus Capital Partners
Deal Type Add-on Acquisition

Target

Xelerated AB

Stockholm, Sweden
Xelerated AB is a fabless semiconductor company and engages in the high-throughput network processor (NPU) market. The Xelerated solution bridged the gap between generalised multi-core NPU designs that are costly and require high-power consumption, and ASIC-based solutions that are cheaper but lack customisation. The Xelerated solution offers the ability to perform a reasonable amount of customisation at a price point and with power consumption figures closer to those of an ASIC (application-specific integrated circuit).

Search 214,600 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Marvell

Wilmington, Delaware, United States
Category Company
Founded 1995
Sector Semiconductors
Employees7,042
Revenue 5.8B USD (2025)
DESCRIPTION
Entrance to Marvell's corporate campus in Santa Clara, California.
Entrance to Marvell's corporate campus in Santa Clara, California.

Marvell is a fabless semiconductor company. Marvell’s U.S. operating subsidiary is based in Santa Clara, California and Marvell has international design centers located in China, Europe, Hong Kong, India, Israel, Japan, Malaysia, Singapore, Taiwan and the U.S. Marvell has expertise in microprocessor architecture and digital signal processing, and provides solutions for multiple platforms including high volume storage, mobile and wireless, networking, consumer and green products. Marvell was founded in 1995 and is based in Wilmington, Delaware.

DEAL STATS #
Overall 8 of 15
Sector: Semiconductors M&A 8 of 14
Type: Add-on Acquisition M&A Deals 4 of 10
Country: Sweden M&A 1 of 1
Year: 2012 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-08-19 Diseno de Sistemas en Silicio S.A.

Paterna, Spain

Diseno de Sistemas en Silicio S.A. is a supplier of high speed semiconductor solutions for powerline communications.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-23 Annapurna Labs

Yokneam, Israel

Annapurna Labs Ltd. is a manufactur of chip circuits in Israeli.

Sell $350M

Seller(S) 2

SELLER

Alta Partners

Jackson, Wyoming, United States

Investor Investor Investor Investor

Category Venture Capital Firm
Founded 1996
PE ASSETS 2.6B USD
Size Large
Type Sector Focused
DESCRIPTION

Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.

DEAL STATS #
Overall 55 of 85
Sector: Semiconductors M&A 2 of 2
Type: Add-on Acquisition M&A Deals 38 of 45
Country: Sweden M&A 2 of 2
Year: 2012 M&A 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-01-02 Azelon Pharmaceuticals

West Conshohocken, Pennsylvania, United States

Azelon Pharmaceuticals is developing a novel parathyroid hormone (PTH) analog called Ostabolin-C™ for the treatment of osteoporosis which has completed Phase II trials. The Company has other Ostabolin-C™ programs in clinical development.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-02-08 ChemoCentryx

San Carlos, California, United States

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx was incorporated in 1996 and is headquartered in San Carlos, California.

Sell -
SELLER

Amadeus Capital Partners

Investor Investor Investor Investor Investor

Category Venture Capital Firm
Founded 1997
PE ASSETS 1.3B USD
Size Large
Type Sector Focused
DESCRIPTION

Amadeus Capital Partners is an early late-stage investor in high growth European technology companies. Specific areas of interest include AI & machine learning, online consumer services, cybersecurity, digital health and medical technology, digital media, enterprise SaaS, fintech, and insurtech. Amadeus Capital Partners was formed in 1997 and is based in London, United Kingdom.

DEAL STATS #
Overall 4 of 26
Sector: Semiconductors M&A 1 of 2
Type: Add-on Acquisition M&A Deals 3 of 20
Country: Sweden M&A 2 of 2
Year: 2012 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-01-04 Unruly Group

London, United Kingdom

Unruly Group Ltd. is an ad tech company that gets videos watched, tracked and shared across the Open Web.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-01-09 Glysure

Abingdon, United Kingdom

Glysure Ltd. is a developer of in-hospital continuous blood glucose monitoring systems using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).

Buy -
Mergr

Solution for

Product

Company

Legal